Zionexa is pleased to welcome Artur Shchukin to the Zionexa team as the RA & QA Manager. His mission will be to lead the Regulatory Affairs and Quality Assurance efforts of Zionexa US.
Created in May 2018, Zionexa is an international company developing and commercializing Molecular Imaging Companion Diagnostics (CDx) for targeted therapies in Oncology aimed at improving patients’ pathway and quality of life. Zionexa is actively working on developing its pipeline of molecules and Corinne will support this thanks to her regulatory expertise, in order for Zionexa to commercialize new biomarkers in the U.S. and Europe.
Artur Shchukin joins Zionexa’s New York office with a solid experience in pharmaceutical regulatory affairs and quality assurance. Most recently he was with Mt. Sinai Hospital in New York City where he worked on clinical and regulatory aspects of drug development. His experience also includes Ampak Company, Inc., DKMS and Propper Manufacturing. He has a Masters’ Degree in Regulatory Affairs & Quality Assurance from Temple University of Pharmacy and a B.A. in Chemistry from City University of New York Brooklyn College.
“I share Zionexa’s mission to bring groundbreaking, safe and efficacious drugs to people in need.”, Artur Shchukin said.
Commenting on Artur’s new assignment at Zionexa, Peter Webner, Zionexa U.S. CEO: “The team is looking forward to welcome Artur as he will be an asset for our Regulatory Affairs and Quality Assurance missions. Thanks to his wealthy experience, we are sure that he will bring success to our projects in the U.S.”
Please join us in welcoming Artur to the Zionexa team.